BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 83.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 331,920 shares of the medical research company’s stock after purchasing an additional 150,969 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.10% of Agilent Technologies worth $21,309,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Advisor Group Inc. boosted its holdings in Agilent Technologies by 0.3% in the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after purchasing an additional 10 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in Agilent Technologies by 0.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after purchasing an additional 35 shares during the period. Veritable L.P. boosted its holdings in Agilent Technologies by 0.4% in the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after purchasing an additional 40 shares during the period. Balentine LLC boosted its holdings in Agilent Technologies by 2.9% in the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares during the period. Finally, Kingfisher Capital LLC boosted its holdings in Agilent Technologies by 0.3% in the 2nd quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock valued at $1,343,000 after purchasing an additional 58 shares during the period.
Agilent Technologies, Inc. (A) opened at $65.89 on Thursday. Agilent Technologies, Inc. has a 52-week low of $44.11 and a 52-week high of $70.93. The company has a market cap of $21,185.94, a price-to-earnings ratio of 27.78, a P/E/G ratio of 1.99 and a beta of 1.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.96%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the company earned $0.59 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. analysts forecast that Agilent Technologies, Inc. will post 2.58 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be given a dividend of $0.149 per share. The ex-dividend date is Friday, December 29th. This represents a $0.60 annualized dividend and a dividend yield of 0.90%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s payout ratio is currently 25.24%.
In related news, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $65.26, for a total transaction of $326,300.00. Following the sale, the insider now owns 45,143 shares of the company’s stock, valued at $2,946,032.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Didier Hirsch sold 1,200 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $66.00, for a total transaction of $79,200.00. Following the sale, the chief financial officer now directly owns 164,202 shares in the company, valued at approximately $10,837,332. The disclosure for this sale can be found here. Insiders have sold 155,268 shares of company stock worth $10,637,706 in the last quarter.
Several brokerages have commented on A. Morgan Stanley reissued an “overweight” rating on shares of Agilent Technologies in a report on Tuesday, November 14th. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Robert W. Baird reaffirmed a “buy” rating and set a $72.00 price objective on shares of Agilent Technologies in a report on Friday, November 24th. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Bank of America reaffirmed an “equal weight” rating on shares of Agilent Technologies in a report on Tuesday, August 15th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $68.34.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/07/agilent-technologies-inc-a-shares-bought-by-british-columbia-investment-management-corp.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.